Use of physiologically based kinetic modeling-facilitated reverse dosimetry of in vitro toxicity data for prediction of in vivo developmental toxicity of tebuconazole in rats.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Toxicology Letters

• Publication date

  2017-01-15

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1016/j.toxlet.2016.11.017PMID 27890808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of Physiologically Based Kinetic Modeling-Based Reverse Dosimetry to Predict in Vivo Toxicity from in Vitro Data.

  2017cited by this paper
• Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.

  2016cited by this paper
• Use of the ES-D3 cell differentiation assay, combined with the BeWo transport model, to predict relative in vivo developmental toxicity of antifungal compounds.

  2015cited by this paper
• Extended evaluation on the ES-D3 cell differentiation assay combined with the BeWo transport model, to predict relative developmental toxicity of triazole compounds

  2015cited by this paper
• Prediction of in vivo developmental toxicity of all-trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic modeling

  2014cited by this paper
• Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches.

  2013cited by this paper
• pKa Constant Determination of Two Triazole Pesticides: Tebuconazole and Penconazole

  2013cited by this paper
• Combining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose–response curves for developmental toxicity of phenol in rat and human

  2013cited by this paper
• Relative embryotoxic potency of p-substituted phenols in the embryonic stem cell test (EST) and comparison to their toxic potency in vivo and in the whole embryo culture (WEC) assay.

  2012cited by this paper
• Developmental toxicity effects in experimental animals after mixed exposure to endocrine disrupting pesticides

  2012cited by this paper
• Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation

  2012cited by this paper
• Relative developmental toxicity potencies of retinoids in the embryonic stem cell test compared with their relative potencies in in vivo and two other in vitro assays for developmental toxicity.

  2011cited by this paper
• Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010

  2011cited by this paper
• Zebrafish developmental toxicity assay: A fishy solution to reproductive toxicity screening, or just a red herring?

  2011cited by this paper
• A modified cornish pasty method for ex ovo culture of the chick embryo

  2011cited by this paper
• Tutorial on physiologically based kinetic modeling in molecular nutrition and food research.

  2011cited by this paper
• Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice.

  2011cited by this paper
• The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man.

  2010cited by this paper
• A physiologically based biodynamic (PBBD) model for estragole DNA binding in rat liver based on in vitro kinetic data and estragole DNA adduct formation in primary hepatocytes.

  2010cited by this paper
• Relative developmental toxicity of glycol ether alkoxy acid metabolites in the embryonic stem cell test as compared with the in vivo potency of their parent compounds.

  2009cited by this paper
• Systematic studies on the paracellular permeation of model permeants and oligonucleotides in the rat small intestine with chenodeoxycholate as enhancer.

  2008cited by this paper
• Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity

  2007cited by this paper
• Predicted serum folate concentrations based on in vitro studies and kinetic modeling are consistent with measured folate concentrations in humans.

  2006cited by this paper
• An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing.

  2005cited by this paper
• INAUGURAL ARTICLE: Identification of 315 genes essential for early zebrafish development

  2004cited by this paper
• Alternative Approaches Can Reduce the Use of Test Animals under REACH.

  2004cited by this paper
• Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination.

  2004cited by this paper
• Impact of protein binding on the availability and cytotoxic potency of organochlorine pesticides and chlorophenols in vitro.

  2002cited by this paper
• Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs

  2002cited by this paper
• The ECVAM International Validation Study on In Vitro Embryotoxicity Tests: Results of the Definitive Phase and Evaluation of Prediction Models

  2002cited by this paper
• Methods of in vitro toxicology.

  2002cited by this paper
• In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: effect of Helicobacter pylori.

  2002cited by this paper
• Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.

  2000cited by this paper
• Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat.

  2000cited by this paper
• Estimation of systemic toxicity of acrylamide by integration of in vitro toxicity data with kinetic simulations.

  1999cited by this paper
• Physiological Parameter Values for Physiologically Based Pharmacokinetic Models

  1997cited by this paper
• In vivo metabolism of butadiene by mice and rats: a comparison of physiological model predictions and experimental data.

  1994cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• Gastric emptying of liquids and solids in the portal hypertensive rat

  1990cited by this paper
• Changes in plasma albumin concentration, synthesis rate, and mRNA level during acute inflammation.

  1986cited by this paper

• A preliminary evaluation of the applicability of the in vitro to in vivo extrapolation approach to quantitative risk assessment.

  2026cites this paper
• Comparative assessment of different alternatives to animal models for developmental toxicity prediction using physiologically based toxicokinetic modelling approach: A case study of hexaconazole, an azole fungicide.

  2025cites this paper
• Scientific Opinion on the application of physiologically based kinetic (PBK) modelling for the quantitative in vitro to in vivo extrapolation (QIVIVE) of developmental neurotoxicity in vitro battery (DNT IVB) data for pesticide active substances

  2025cites this paper
• Use of physiologically based kinetic modeling to predict neurotoxicity and genotoxicity of methylglyoxal in humans

  2024cites this paper
• Can TK-TD modelling bridge the gap between in vitro and in vivo mammalian toxicity data?

  2024cites this paper
• PBK models to predict internal and external dose levels following oral exposure of rats to imidacloprid and carbendazim

  2024cites this paper
• In vivo Tebuconazole administration impairs heart electrical function and facilitates the occurrence of dobutamine-induced arrhythmias: Involvement of reactive oxygen species.

  2024cites this paper
• Predicting the in vivo developmental toxicity of fenarimol from in vitro toxicity data using PBTK modelling-facilitated reverse dosimetry approach.

  2024cites this paper
• Levels, Toxic Effects, and Risk Assessment of Pyrrolizidine Alkaloids in Foods: A Review

  2024cites this paper
• Quantitative in vitro to in vivo extrapolation for human toxicology and drug development

  2024cites this paper
• Species specific kinetics of imidacloprid and carbendazim in mouse and rat and consequences for biomonitoring

  2024cites this paper
• Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – Part IV: the ECETOC and CLE Proposal for a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS)

  2023cites this paper
• Derivation of a Human In Vivo Benchmark Dose for Bisphenol A from ToxCast In Vitro Concentration Response Data Using a Computational Workflow for Probabilistic Quantitative In Vitro to In Vivo Extrapolation

  2022influential citation
• Use of Physiologically Based Kinetic Modeling-Facilitated Reverse Dosimetry to Predict In Vivo Acute Toxicity of Tetrodotoxin in Rodents

  2022cites this paper
• New approach methodologies: A quantitative in vitro to in vivo extrapolation case study with PFASs

  2022cites this paper
• DNA adducts as link between in vitro and in vivo carcinogenicity – A case study with benzo[a]pyrene

  2022cites this paper
• Advancing New Approach Methodologies (NAMs) for Tobacco Harm Reduction: Synopsis from the 2021 CORESTA SSPT—NAMs Symposium

  2022cites this paper
• IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making

  2022cites this paper
• Residual Level, Histology, and Blood Biochemistry of Tebuconazole: A Repeated Dose 28-Day Oral Toxicity Study in Pigs

  2022cites this paper
• New insights into potential estrogen agonistic activity of triazole fungicides and coupled metabolic disturbance.

  2021cites this paper
• Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.

  2021cites this paper
• Derivation of a Human In Vivo Benchmark Dose for Perfluorooctanoic Acid From ToxCast In Vitro Concentration–Response Data Using a Computational Workflow for Probabilistic Quantitative In Vitro to In Vivo Extrapolation

  2021influential citation
• Tebuconazole induces liver injury coupled with ROS-mediated hepatic metabolism disorder.

  2021cites this paper
• Predicting the in vivo developmental toxicity of benzo[a]pyrene (BaP) in rats by an in vitro–in silico approach

  2021cites this paper
• PBK Model‐Based Prediction of Intestinal Microbial and Host Metabolism of Zearalenone and Consequences for its Estrogenicity

  2021cites this paper
• Integrating in vitro chemical transplacental passage into a generic PBK model: A QIVIVE approach.

  2021cites this paper
• - Food Science of Animal Resources -

  2021cites this paper
• Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone

  2020cites this paper
• Defining in vivo dose‐response curves for kidney DNA adduct formation of aristolochic acid I in rat, mouse and human by an in vitro and physiologically based kinetic modeling approach

  2020cites this paper
• Predicting the Acute Liver Toxicity of Aflatoxin B1 in Rats and Humans by an In Vitro–In Silico Testing Strategy

  2020cites this paper
• Development of a Generic Physiologically Based Kinetic Model to Predict In Vivo Uterotrophic Responses Induced by Estrogenic Chemicals in Rats Based on In Vitro Bioassays

  2019cites this paper
• Novel strategies for risk assessment of pyrrolizidine alkaloids

  2019influential citation
• The in vivo developmental toxicity of diethylstilbestrol (DES) in rat evaluated by an alternative testing strategy

  2019cites this paper
• Biotransformation and bioactivation reactions – 2018 literature highlights

  2019cites this paper
• Combining In Vitro Data and Physiologically Based Kinetic Modeling Facilitates Reverse Dosimetry to Define In Vivo Dose–Response Curves for Bixin‐ and Crocetin‐Induced Activation of PPARγ in Humans

  2019cites this paper
• Integrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment-A case study of troglitazone.

  2019cites this paper
• Use of physiologically based kinetic modelling-facilitated reverse dosimetry to convert in vitro cytotoxicity data to predicted in vivo liver toxicity of lasiocarpine and riddelliine in rat.

  2018cites this paper
• Alternative developmental toxicity models for assessing the in vivo embryotoxicity of azoles

  2018cites this paper
• In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds

  2018cites this paper
• A Computational Workflow for Probabilistic Quantitative in Vitro to in Vivo Extrapolation

  2018cites this paper
• In vitro to in vivo extrapolation of effective dosimetry in developmental toxicity testing: Application of a generic PBK modelling approach

  2017cites this paper
• Towards a generic physiologically based kinetic model to predict in vivo uterotrophic responses in rats by reverse dosimetry of in vitro estrogenicity data

  2017cites this paper
• Towards an alternative human health risk assessment paradigm

  2017cites this paper
• Alternative testing strategies for predicting developmental toxicity of antifungal compound

  2016cites this paper